Exchange: NASDAQ·Updated 05:26 PM EDT

TNGXTango Therapeutics Inc

$30.26
$0.48
(1.63%)
Today
Closed $29.94
$0.32
(1.07%)
After Hours
EarningsAug 5
Mkt Cap$4.8B
Vol2.14M
News
all
press releases
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
Zacks
News Placeholder
More News
News Placeholder
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
Zacks
News Placeholder
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.
Zacks
News Placeholder
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Zacks
News Placeholder
Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are On Investors' Radars Today
AAPL, SUNE, TNGX, APLD, CBRS were among the stocks seen trending on Monday, June 8, 2026.read more...
Benzinga
News Placeholder
The Hottest Stocks Traders Are Chasing into the Closing Bell
As traders head into the final stretch of today's session, investor attention remains focused on a diverse group of emerging growth companies. $NTHI, $TNGX, $ABAT, $OCC, $INHD, $NPT, $BYAH, $GLXY, $ZVRA, $ASTI
24-7 Market News
News Placeholder
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’
Tango Therapeutics’ experimental cancer drug Vopimetostat, in combination with Daraxonrasib, achieved a 92% objective response rate in patients with advanced pancreatic cancer.
Stocktwits
News Placeholder
Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday
U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC, SRAD, AIAI, ALOY, and GENI.read more...
Benzinga
News Placeholder
FDA Milestones Fueling Expansion
The biotechnology sector delivered several notable developments. $TNGX, $NTHI, $AIM, $AZN, $NRIX, $NYXH
24-7 Market News
News Placeholder
Why Is Tango Therapeutics Stock Soaring Monday?
Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat combo driving TNGX stock up.read more...
Benzinga
<
1
2
...
>

Advertisement|Remove ads.